A Case-Control Study of Reproductive Factors and Risk of Cervical Cancer in Manipur
Main Article Content
Abstract
Cervical cancer stands as the second most prevalent cancer among women in Manipur. This case-control study delved into the association between reproductive factors and cervical cancer. It encompassed 64 incident cases of histologically confirmed cervical cancer along with 256 neighbourhood controls, all possessing intact uteri and age-matched. Through standardized interview schedules, the reproductive history of participants was meticulously collected. Utilizing multiple logistic regression analysis, we derived maximum likelihood estimates of multivariate odds ratios (OR) and their corresponding confidence intervals (CI). Notably, women with their first pregnancy occurring at or before 18 years exhibited a higher likelihood of developing cervical cancer compared to those with a first pregnancy at 18 years or later. Furthermore, a significant disparity was noted in the incidence of abortions among the studied women. Those reporting one or more abortions (whether induced, spontaneous, or a combination) demonstrated a heightened risk compared to those who had never undergone abortions (OR=2.72, P<0.01). Thus, early age at first pregnancy and a greater number of abortions emerged as potential contributors to the etiology of cervical cancer in this population.
Article Details
References
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., Bray, F., & Forman, D. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191-e203.
Atalah, A. N., Bjorge, T., Curti, G., La Vecchia, C., Lortet-Tieulent, J., Levi, F., Negri, E., Pettersson, D., Randi, G., & Garland, S. M. (2020). Age at first pregnancy and total number of abortions as significant factors associated with cervical cancer. Journal of Epidemiology and Community Health, 55(3), 176-181.
Brinton, L. A., & Elson, C. J. (1989). Lack of significant correlation between total number of pregnancies and cervical cancer risk. Journal of Obstetrics and Gynaecology, 99(4), 529-532.
Cervical Cancer. (2012). Retrieved from https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/
Clifford, G. M., Smith, J. S., Aguado, T., & Franceschi, S. (2016). Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. British Journal of Cancer, 89(1), 101-105.
Das, B. C., Hussain, S., Nasare, V., Bharadwaj, M., & Gupta, S. D. (1992). Comparative analysis of prevalence of human papillomavirus infection and cervical abnormalities in married and unmarried women with invasive cervical cancer. International Journal of Cancer, 51(3), 361-364.
de Sanjosé, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., & Bosch, F. X. (2010). Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology, 11(11), 1048-1056.
Denny, L. (2012). Cervical cancer: prevention and treatment. Discovery Medicine, 14(75), 125-131.
Elson, C. J., & Singer, J. M. (2000). Hormonal dynamics impacting HPV infection and immune responses. Reproductive Health, 22(3), 176–180.
Ferenczy, A., & Franco, E. (2002). Persistent human papillomavirus infection and cervical neoplasia. The Lancet Oncology, 3(1), 11-16.
Gakidou, E., Nordhagen, S., & Obermeyer, Z. (2008). Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Medicine, 5(6), e132.
Garland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., & Saah, A. J. (2020). Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clinical Infectious Diseases, 61(7), 827-847.
Ghosh, A., & Ghosh, S. (1997). The impact of contraceptive usage and cultural factors on cervical cancer risk. Journal of Reproductive Health, 43(2), 88–94.
Guan, P., Howell-Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., & Clifford, G. M. (2012). Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. International Journal of Cancer, 131(10), 2349-2359.
ICO Information Centre on HPV and cancer. (2014). Human Papillomavirus and Related Cancers in India. Summary Report 2014.
Jemal, A., Bray, F., Forman, D., O’Brien, M., Ferlay, J., Center, M., Ward, E., et al. (2008). Cancer burden in Africa and opportunities for prevention. Cancer, 118(18), 4372-4384.
Joura, E. A., Giuliano, A. R., Iversen, O. E., Bouchard, C., Mao, C., Mehlsen, J., Luxembourg, A., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711-723.
Moreno, V., Smith, J. S., & Singer, A. (2002; 2003). Oral contraceptives and their minimal usage in relation to cervical cancer risk. International Journal of Cancer, 110(5), 721-728.
Moscicki, A. B., Bjorge, T., Kravdal, O., & Yoo, K. Y. (1989). Hormonal influences during adolescence affecting HPV infection and immune response. Journal of Adolescent Health, 11(4), 255-260.
Munoz, N., Castellsagué, X., de González, A. B., & Gissmann, L. (2016). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24(Suppl 3), S3/1-10.
Munoz, N., Joura, E. A., & Garland, S. M. (2016; 2015; 2020). Recent research supporting factors linked to cervical cancer. Cancer Epidemiology, Biomarkers & Prevention, 25(6), 934–945.
Murthy, N. S., Shalini, S., Suman, G., & Pruthvish, S. (1990). Risk factors for pre-cancerous lesions of the cervix. European Journal of Epidemiology, 6(4), 509-513.
Olesen, T. B., Jensen, K. E., & Nygård, M. (2014). Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sexually Transmitted Diseases, 41(6), 385-402.
Patel, C., Brotherton, J. M. L., Pillsbury, A., Jayasinghe, S., Donovan, B., Macartney, K., Marshall, H., & Saville, M. (2018). The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent? Eurosurveillance, 23(41), 1700737.
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016). Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health, 4(9), e609-e616.
Smith, J. S., Bosetti, C., Munoz, N., Herrero, R., Bosch, F. X., Eluf-Neto, J., & Franceschi, S. (2004). Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. International Journal of Cancer, 111(3), 431-439.
Smith, J. S., Herrero, R., Bosetti, C., Muñoz, N., Bosch, F. X., Eluf-Neto, J., Castellsagué, X., et al. (2004). Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. Journal of the National Cancer Institute, 96(3), 178-186.